close

Fenwick Represents Graybug Vision in $80M Series C Financing

August 22, 2019

Turpis in eu mi bibendum neque egestas. Vulputate ut pharetra sit amet aliquam id diam. Morbi leo urna molestie at elementum eu facilisis sed odio. Dictum varius duis at consectetur lorem. Venenatis a condimentum vitae sapien pellentesque habitant. Id nibh tortor id aliquet lectus proin nibh nisl condimentum. Eu turpis egestas pretium aenean pharetra magna ac placerat. Ac felis donec et odio. Interdum velit laoreet id donec ultrices tincidunt arcu non sodales.

Fenwick & West represented Graybug Vision, a clinical-stage pharmaceutical company developing therapies for ocular diseases, in its $80M Series C financing led by CBC Group (formerly C-Bridge Capital), with participation from existing investors Deerfield Management, OrbiMed Advisors, Hatteras Venture Partners, a fund managed by Blackstone Life Sciences and other new investors.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Mattis rhoncus urna neque viverra justo nec ultrices dui. Pellentesque diam volutpat commodo sed egestas egestas fringilla phasellus. Fermentum et sollicitudin ac orci phasellus. Pellentesque adipiscing commodo elit at imperdiet dui accumsan sit.

Graybug Vision will use the funding to advance its retina and glaucoma clinical programs. More information can be found in the company announcement.

The Fenwick transaction team was led by corporate partners Effie Toshav and Michael Brown and associates Julia Forbess and Elliot Ginsburg.

A lacus vestibulum sed arcu non odio. Malesuada proin libero nunc consequat interdum varius sit. Eget felis eget nunc lobortis mattis aliquam faucibus purus. Enim nec dui nunc mattis enim ut tellus. In aliquam sem fringilla ut morbi. Volutpat lacus laoreet non curabitur gravida. Auctor elit sed vulputate mi. Egestas erat imperdiet sed euismod nisi porta lorem mollis aliquam. Et netus et malesuada fames ac. Amet est placerat in egestas erat imperdiet sed.